Pfizer Inc gets regulatory nod to treat leukemia

By Admin
Worlds largest drugmaker Pfizer Inc has secured regulatory approval to treat one of the four most common types of leukemia, the news reports said. The...

World’s largest drugmaker Pfizer Inc has secured regulatory approval to treat one of the four most common types of leukemia, the news reports said.

The Food and Drug Administration also approved the drug known as Bosulif for adults with the previously treated chronic myeloid leukemia who also have an abnormality known as Philadelphia chromosome, the New-York-based company said.

According to the American Cancer Society in Atlanta, there are expected to be about 5,400 new cases and 601 deaths from blood cancer this year.

The drug Bosulif will compete with Novartis AG’s Tasigna and Bristol-Myers Squibb Co’s Sprycel.

According to the average estimate of six analysts, Pfizer’s treatment is expected to generate $71 million in sales in 2015.

Jorge Cortes, a professor of medicine at the University of Texas MD Anderson Cancer Center, and a lead investigator of the Pfizer-sponsored study on the drug said, “Bosulif is an important new addition to the CML treatment landscape.”

This is Pfizer’s third oncology drug approved in the past 13 months, preceded by Xalkori for lung cancer and Inlyta for the advanced kidney cancer.

Chronic myeloid leukemia produces an excess of white blood cells and is one of the four main types of leukemia that accounts for 15% of all leukemia worldwide.

Pfizer is an American multinational pharmaceutical company based in New York and has its research headquarters in Groton, Connecticut in U.S. It is also the world’s largest pharmaceutical company by revenues.

Share
Share

Featured Articles

Amazon Prime & One Medical to revolutionise healthcare

Amazon's vision for health is one that is affordable & convenient. Together, One Medical & Amazon Prime are a prescription for better healthcare

Creating robust pharma supply chains with delivery devices

John Swift, Head of Supply Chain at Owen Mumford Pharmaceutical Services, discusses how lifecycle management is key to a safe supply of pharma products

From Ukraine to Myanmar, reports reveal attacks on hospitals

Reports from the Centre for Information Resilience shows Russian army attacked Ukrainian hospitals & Myanmar’s military Junta targeted medical facilities

The use of AI in biopharma according to L.E.K. Consulting

Technology & AI

Novartis Kisqali minimises breast cancer recurrence

Medical Devices & Pharma

Rimidi CEO Lucienne Marie Ide on improving patient outcomes

Hospitals